{
    "nctId": "NCT01144468",
    "briefTitle": "Effects of Exemestane on Bone Strength",
    "officialTitle": "Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Osteoporosis, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 351,
    "primaryOutcomeMeasure": "Mean Percent Change in Total Volumetric Bone Mineral Density (BMD) Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-PQCT) From Baseline to 24 Months",
    "eligibilityCriteria": "Inclusion Criteria:\n\nWomen participating in the MAP.3 clinical trial at centres with access to HR-pQCT\n\nExclusion Criteria:\n\n1. Women with osteoporosis;\n2. Women with T-score of -2.0 or below at the lumbar spine (L1-L4), total hip or femoral neck;\n3. Women with a fragility fracture after age 40;\n4. Women who have been on any bone drug, such as hormone replacement therapy, selective estrogen receptor modulators, bisphosphonates, teriparatide, parathyroid hormone, sodium fluoride, strontium, calcitonin and high dose vitamin D (more than 2000iu of vitamin D3 daily),in the past 3 months;\n5. Women who have ever been on a bisphosphonate for more than 6 months;\n6. Women who have ever been on strontium for more than 1 month;\n7. Women who are on chronic oral steroids (the equivalent of 5mg of prednisone a day or higher for more than 2 weeks within the past 6 months and will likely require ongoing therapy);\n8. Women with Paget's disease, Cushing's disease, hyperparathyroidism, uncontrolled hyperthyroidism or other metabolic bone diseases;\n9. Women with decompensated diseases of the liver, bowel, kidney, pancreas, lung, or heart.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}